Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial assessing the safety and tolerability of a combination incorporating Ampligen, celecoxib with or without Intron A in patients with early-stage triple negative breast cancer (TNBC)

Next Previous
Trial Profile

A phase I trial assessing the safety and tolerability of a combination incorporating Ampligen, celecoxib with or without Intron A in patients with early-stage triple negative breast cancer (TNBC)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Rintatolimod (Primary) ; Antineoplastics
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 12 Sep 2019 New trial record
  • 10 Sep 2019 According to an AIM ImmunoTech media release, Roswell Park has received the FDA authorization to proceed with the study.
  • 10 Sep 2019 According to an AIM ImmunoTech media release, the principal investigator for this study is Dr. Shipra Gandhi and this study will be conducted at Roswell Park Comprehensive Cancer Center.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top